Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aramchol CYP3A4 Inhibition Study in Healthy Volunteers
NCT03760848Phase 1Completed
- Sponsor
- Galmed Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aramchol in Nonalcoholic steatohepatitis (NASH), sponsored by Galmed Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 5 more. Started Nov 2018; status: completed.
02
Drugs
aramchol
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03760848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760848.